Some with severe sickle cell disease in England will now be able to access landmark CRISPR gene editing therapy, according to ...

LONDON — People in England with sickle cell disease will now be able to access the world’s first CRISPR-based medicine under a pricing and reimbursement agreement reached between U.K. health ...

The £1.65 million gene therapy called exa-cel, also known under the brand name Casgevy, uses a Nobel Prize-winning gene-editing technology called Crispr. Some 1,700 patients with sickle cell ...

The CRISPR-based gene therapy Casgevy (exagamglogene autotemcel) has been made available to patients with sickle cell disease in England, following positive guidance issued by the National ...

to allow patients with sickle cell disease (SCD) to access its gene-edited therapy Casgevy, developed with CRISPR Therapeutics (NASDAQ:CRSP). The deal comes after the National Institute for Health ...